MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
18.40
-0.08
-0.43%
After Hours: 18.00 -0.4 -2.17% 16:52 06/26 EDT
OPEN
18.43
PREV CLOSE
18.48
HIGH
19.43
LOW
17.90
VOLUME
2.73M
TURNOVER
--
52 WEEK HIGH
19.43
52 WEEK LOW
5.68
MARKET CAP
1.13B
P/E (TTM)
-4.9438
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Reaffirms Their Buy Rating on Cullinan Management (CGEM)
TipRanks · 3d ago
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed?
Simply Wall St · 3d ago
Weekly Report: what happened at CGEM last week (0615-0619)?
Weekly Report · 5d ago
Cullinan Therapeutics Shareholders Back Directors and Governance Measures
TipRanks · 06/16 22:44
Cullinan Therapeutics shareholders elect two Class III directors at annual meeting
PUBT · 06/16 21:18
Weekly Report: what happened at CGEM last week (0608-0612)?
Weekly Report · 06/15 09:57
Cullinan Therapeutics: Heading Toward Paydirt
Seeking Alpha · 06/11 15:41
Cullinan Therapeutics Price Target Maintained With a $37.00/Share by Wedbush
Dow Jones · 06/11 13:54
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.